Clinical utility of chlormadinone acetate (Lutoral™) in frozen‐thawed embryo transfer with hormone replacement
Autor: | Daichi Inoue, Yoshimasa Asada, Noritaka Fukunaga, Megumi Sonohara, Yukio Hattori, Rie Ito, Yoshiki Hashiba |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
lcsh:QH471-489 medicine.drug_class orally active progestin Luteal phase lcsh:Diseases of the endocrine glands. Clinical endocrinology Andrology 03 medical and health sciences Chlormadinone acetate chemistry.chemical_compound 0302 clinical medicine luteal phase support assisted reproductive technology medicine lcsh:Reproduction Pregnancy 030219 obstetrics & reproductive medicine lcsh:RC648-665 endometrial preparation business.industry Original Articles Cell Biology medicine.disease Embryo transfer frozen‐thawed embryo transfer Pregnancy rate 030104 developmental biology Reproductive Medicine chemistry Hypospadias Original Article business Live birth Progestin |
Zdroj: | Reproductive Medicine and Biology, Vol 18, Iss 3, Pp 290-295 (2019) Reproductive Medicine and Biology |
ISSN: | 1445-5781 1447-0578 |
Popis: | Purpose The clinical utility of chlormadinone acetate tablets (Lutoral™), an orally active progestin which has been available since June 2007, was compared to an in‐house vaginal suppository formulation of progesterone used between 2006 and 2007 for assisted reproductive technology (ART). Methods We retrospectively evaluated the efficacy and safety of chlormadinone acetate by comparing the pregnancy rates and the incidences of birth defects and hypospadias in frozen‐thawed embryo transfer cycles using the in‐house vaginal progesterone and those using chlormadinone acetate for luteal phase support. Results The pregnancy rates in the frozen‐thawed embryo transfer cycles were 31.2% (259/831) with vaginal progesterone for luteal phase support and 31.6% (4228/13 381) with chlormadinone acetate (no significant difference). In the cycles resulting in live birth following administration of chlormadinone acetate between July 2007 and December 2015, the incidence of birth defects was 2.8% (80/2893), and the incidence of hypospadias was 0.03% (1/2893). Conclusions These results indicate that the pregnancy rate following frozen‐thawed embryo transfer using chlormadinone acetate for luteal phase support was comparable with that using vaginal progesterone, with no increased risk of birth defects, including hypospadias, which has been a concern following the use of progestins. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |